Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

September 10, 2007 10 September, 2007

Sertoli Cells Successfully Engineered to Secrete Insulin and are Effective in Preclinical Models of Diabetes

Kelowna, British Columbia - September 10, 2007 - Sernova Corp. (TSX-V: SVA) would like to congratulate Dr. Jannette Dufour and Ms. Katie Halley who have reversed diabetes in an animal model by genetically engineering Sertoli cells to secrete insulin. Sernova owns the exclusive patent rights for the therapeutic use of Sertoli cells to treat diseases including diabetes. These results support the concept that Sertoli cells could be an "implanted drug factory" for numerous disease applications.

"Dr. Dufour's research is an important finding for the future treatment of diabetes, and other diseases caused by a deficiency in a hormone, protein, or enzyme, because it appears Sertoli cells can be made to secrete any number of therapeutic factors," commented Dr. David White, Sernova's Principal Researcher. "We know from our studies that the immunoprotective properties of Sertoli cells make them ideal candidates for a drug delivery system that can be transplanted without the need for anti- rejection drugs."

Stated Justin Leushner, Sernova's CEO, "These findings demonstrate the versatility of our Sertoli technology which has been protected in Sernova's many worldwide patents and patent applications. Our core Sertolin�¢ program of using Sertoli cells in combination with islet cells as a treatment for diabetes is continuing. Concurrently we will explore the possibilities for developing therapeutic applications based on these exciting results."

Dr. Dufour, who is a member of Sernova's Scientific Advisory Board and is on faculty at Texas Tech University Health Sciences Center, will present the study at the joint conference of the Cell Transplant Society, International Pancreas and Islet Transplant Association, and International Xenotransplantation Association being held in Minneapolis on September 15 - 20, 2007.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin� cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493